Jonathan Strosberg, MD, Moffitt Cancer Center, Tampa, FL, highlights the treatment options currently available for various unresectable well-differentiated neuroendocrine tumors (NETs) and discusses novel drugs entering the market; standard first line treatment often involves somatostatin analogues, afinitor is a popular treatment option in liver dominant, pancreatic and other tumors, although the efficacy of afinitor in liver dominant tumors is questionable. 177Lu-DOTATATE is used in midgut and pancreatic tumors, treatment options for the latter also include sunitinib and chemotherapy options. Recently, the multi-tyrosine kinase inhibitor surufatinib has been shown to significantly improve progression-free survival (PFS), in two populations of treatment naïve patients with NETs, with an overall response rate (ORR) of 10-20%, these results suggest that surufatinib could soon be approved to treat NETs. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.